For more information about products within the Pathway Portfolio, please click here for prescribing information
Pain
The Pathway Portfolio is Aspire Pharma’s branded generic portfolio with products covering a wide range of therapy areas, including: CNS, Respiratory, Cardiovascular, Pain and Urology.
Each product in the portfolio has its own key offerings, ranging from:
- A full range of strengths available1
- A first strength to market1
- Simpler dosing which may help some patients with concordance and compliance1-2
- The first brand to market1
All of which create a wider offering to patients.
Pathway to Partnership:
Trusted Brands:
- Bioequivalent to brand originators3
- Available from mainline wholesalers
Bespoke Support:
- Price guarantee
- Individualised rebates on request
Sevodyne® (buprenorphine) transdermal patches
Indicated for the treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia4.
69% savings across all 4 strengths on the UK Drug Tariffs1.
Sevodyne® could reduce the average ICS/ICB prescribing costs of buprenorphine transdermal patches by an average of £506,171 per annum, saving up to £21.3 million annually across the NHS5*.
Please click on the buttons to download Sevodyne patient materials. If you would like to order printed versions of any of the materials listed, please click here to contact one of our representatives.
References:
*Average ICS is based on 4 x Moving Quarterly Turnover (MQT) divided by 42 ICS/ICB’s
- UK Drug Tariff (accessed October 2024)
- Kyoko Higashiet al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatric Disease and Treatment, 2013; 9: 119–131 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552550/
- Data on file, 1010067149 v6.0 September 2023 Bioequivalence data
- Sevodyne® SmPC (accessed October 2024)
- Insypher 10100831045 v 21.0 August 2024, GPPLPD Date Range: May-24 – Jul-24
XLW1010311G2_OCT2024
